- $6.8 BnWorld market, 2023
- $11.8 BnProjected, 2033
- 5.7%Growth a year (CAGR)
- 232Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$2.9 Bn
3.7% a year · 42% of the world -
2
China
$547 Mn
7.2% a year · 8% of the world -
3
Canada
$544 Mn
5.7% a year · 8% of the world -
4
Japan
$423 Mn
6.2% a year · 6.2% of the world -
5
Germany
$249 Mn
3.9% a year · 3.7% of the world -
6
France
$187 Mn
4.7% a year · 2.8% of the world -
7
UK
$177 Mn
3.7% a year · 2.6% of the world -
8
Brazil
$170 Mn
6.7% a year · 2.5% of the world -
9
Italy
$163 Mn
5.2% a year · 2.4% of the world -
10
Ecuador
$136 Mn
6.3% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
SpainCardiovascular Health Supplements by country and region
India
Saudi Arabia
Mexico
Australia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 12,936 papers since 2021
- Mitochondrial DNA in cardiovascular disease. Atherosclerosis, 2026
- Building Consensus Among Intensive Care Nurses on the Scope of Practice for Registered Nurses Deployed to Intensive Care During Surge Events: A Real-Time Delphi Study. Nursing in critical care, 2026
- Artificial Intelligence-Enhanced Electrocardiography for the Detection of Hypertrophic Cardiomyopathy in Athletes: A Systematic Review of Diagnostic Accuracy and External Validity. Cureus, 2026
- GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes with CKD stages 2-4: a target trial emulation. Diabetology & metabolic syndrome, 2026
- High Cholesterol Facilitates Ovarian Androgen Production and Contributes to the Development of Polycystic Ovary Syndrome. Phenomics (Cham, Switzerland), 2026
Patients: High blood pressure (ages 30–79)
| Place | Value | Year |
|---|---|---|
| World | 33.1 | 2019 |
| Australia | 29.3 | 2019 |
| Brazil | 45.0 | 2019 |
| Canada | 22.1 | 2019 |
| China | 27.3 | 2019 |
| Ecuador | 27.2 | 2019 |
| Egypt | 38.2 | 2019 |
| France | 29.1 | 2019 |
| Germany | 29.7 | 2019 |
| India | 31.1 | 2019 |
| Italy | 33.8 | 2019 |
| Japan | 31.4 | 2019 |
| Kenya | 33.2 | 2019 |
| Malaysia | 40.8 | 2019 |
| Mexico | 32.1 | 2019 |
| New Zealand | 30.9 | 2019 |
| Philippines | 33.8 | 2019 |
| Russia | 44.3 | 2019 |
| Saudi Arabia | 34.0 | 2019 |
| Singapore | 31.5 | 2019 |
| South Africa | 44.1 | 2019 |
| Spain | 27.2 | 2019 |
| Thailand | 29.2 | 2019 |
| UAE | 41.4 | 2019 |
| UK | 26.4 | 2019 |
| US | 31.6 | 2019 |
Compare Cardiovascular Health Supplements side by side
Key companies in Cardiovascular Health Supplements
InVite Health
Herbalife International of America, Inc
Nature’s Way Products, Inc
Nestle
Nordic Naturals
NOW Health Group, Inc
Sanofi S.A
Thorne HealthTech, Inc
USANA Health Sciences
Quick answers
How big is the Cardiovascular Health Supplements market?
The world Cardiovascular Health Supplements market was worth about $6.8 Bn in 2023 and is projected to reach $11.8 Bn by 2033, growing 5.7% a year (CAGR).
Which country has the largest Cardiovascular Health Supplements market?
The US is the largest of the 24 countries we cover, at $2.9 Bn in 2023. India grows fastest, at 8.7% a year.
How many clinical trials are running in Cardiovascular Health Supplements?
ClinicalTrials.gov lists 232 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Cardiovascular Health Supplements?
PubMed lists about 12,936 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Patients: WHO Global Health Observatory. Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.